Idiopathic Multicentric Castleman Disease (iMCD): CDCN 2017 Criteria, TAFRO Variant, and Siltuximab First-Line Therapy
A comprehensive guideline to navigating the CDCN 2017 international consensus diagnostic criteria, recognizing the TAFRO and NOS-IPL subtypes, identifying IL-6-driven systemic inflammation, and selecting siltuximab as first-line anti-IL-6 therapy.
Executive Summary
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by multicentric lymphadenopathy with characteristic hyaline-vascular or plasma cell histology, multi-organ inflammation driven by IL-6 hypersecretion in many patients, and frequent constitutional symptoms with cytopenias, organomegaly, and effusions. The Castleman Disease Collaborative Network (CDCN) 2017 international consensus diagnostic criteria formalize the diagnosis requiring excisional lymph node biopsy, multicentric distribution, at least 2 of 11 minor criteria (laboratory and clinical), HHV-8 negativity by LANA-1 immunohistochemistry, and exclusion of alternative diagnoses. Two distinct iMCD subtypes are now recognized: iMCD-TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, Organomegaly) representing a severe acute syndrome, and iMCD-NOS (which includes the idiopathic plasmacytic lymphadenopathy or IPL variant). First-line therapy for non-severe iMCD is siltuximab (anti-IL-6 monoclonal antibody, 11 mg/kg IV every 3 weeks) or tocilizumab; severe disease and TAFRO require combination siltuximab + high-dose corticosteroids. Refractory disease may require cytotoxic chemotherapy, rituximab, lenalidomide, sirolimus, or JAK inhibitors. Modern 5-year survival approaches 65-77 percent.
Table of Contents
- Castleman Disease Classification and Pathophysiology
- CDCN 2017 iMCD Diagnostic Criteria
- TAFRO and NOS-IPL Subtypes
- Histopathology and Differential Diagnosis
- Siltuximab, Tocilizumab, and Refractory Disease Management
- Practice Insights — Lessons from the Lymphoproliferative Disorders Clinic
- Frequently Asked Questions
S1. Castleman Disease Classification and Pathophysiology
Castleman Disease Classification
Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders unified by characteristic lymph node histology but diverse in etiology, clinical extent, and management. Modern classification by clinical extent and etiology:
| Category | Frequency | Key Features |
|---|---|---|
| Unicentric Castleman Disease (UCD) | ~75% of all CD | Single lymph node region; hyaline-vascular histology predominant; HHV-8 and HIV negative; surgically curable; excellent prognosis |
| HHV-8-associated MCD | Variable (HIV epidemiology) | Occurs in HIV-positive (most common) and other immunocompromised; lymph node LANA-1 positive; rituximab-based treatment |
| POEMS-associated MCD | ~10% of POEMS | Concurrent with POEMS syndrome; managed as part of POEMS treatment |
| Idiopathic Multicentric Castleman Disease (iMCD) | ~10-20% of MCD | HHV-8 negative HIV negative; CDCN 2017 criteria; subtypes TAFRO and NOS |
iMCD Pathophysiology
The pathogenesis of iMCD is incompletely understood but appears to involve dysregulated immune response with cytokine storm, IL-6 being the dominant pathogenic cytokine in many patients. Three potential pathophysiologic models:
Model 1: IL-6-Driven Cytokine Storm
- Excessive IL-6 production from lymph node germinal centers and plasma cells
- IL-6 drives B cell proliferation, plasma cell differentiation, polyclonal hypergammaglobulinemia, acute phase response (CRP elevation)
- IL-6 mediates constitutional symptoms (fever, fatigue, weight loss) and organomegaly
- This subset responds to anti-IL-6 therapy (siltuximab, tocilizumab)
Model 2: Auto-Inflammatory Mechanism
- Innate immune dysregulation independent of IL-6
- Other cytokines including IL-1, VEGF, IL-10, IFN-gamma contribute
- May respond less well to anti-IL-6 therapy
- JAK inhibition (ruxolitinib) and other immunomodulators may be more effective
Model 3: Autoimmune Mechanism
- Autoantibody-mediated pathology in subset of patients
- Overlap with autoimmune lymphoproliferative syndromes
- May respond to rituximab
The heterogeneity of underlying pathophysiology explains the variable response to anti-IL-6 therapy (approximately 34 percent durable response in the pivotal siltuximab trial) and the need for alternative therapeutic targets in refractory disease.
Clinical Features
| Clinical Feature | Frequency in iMCD |
|---|---|
| Multicentric lymphadenopathy | Essentially universal (defining feature) |
| Constitutional B-symptoms (fever, night sweats, weight loss) | 70-90% |
| Hepatosplenomegaly | 70-90% |
| Cytopenias | Anemia 80%, thrombocytopenia 30-50% (more severe in TAFRO) |
| Effusions (pleural, pericardial, ascites) | 30-60% (more prominent in TAFRO) |
| Polyclonal hypergammaglobulinemia | 50-70% (less common in TAFRO) |
| Elevated CRP/ESR | Essentially universal |
| Eruptive cherry hemangiomas / violaceous papules | 10-30% |
| Renal dysfunction | 30-50% (often AA amyloidosis or thrombotic microangiopathy) |
| Hepatic dysfunction | 30-50% |
| Pulmonary involvement (LIP) | 10-20% |
Epidemiology
- Incidence: approximately 5-7 per million annually (all Castleman disease combined)
- iMCD incidence: approximately 1-2 per million annually
- Age: median diagnosis age 40-50 years, broader range than HHV-8 MCD
- Sex: slight male predominance
- HHV-8 status by definition negative
- HIV status by definition negative
S2. CDCN 2017 iMCD Diagnostic Criteria
The CDCN 2017 Criteria Framework
The Castleman Disease Collaborative Network (CDCN) published international consensus diagnostic criteria in 2017 (Blood) that established the formal framework for iMCD diagnosis. All five components are required.
Required Diagnostic Components
1. Histopathology
Histopathologically confirmed Castleman disease on excisional lymph node biopsy, showing either:
- Hyaline-vascular variant: regressed germinal centers (“burned out”), prominent vascular proliferation with sclerosis, onion-skin layering of mantle zones, atrophic dendritic cells
- Plasma cell variant: hyperplastic germinal centers, sheets of plasma cells in interfollicular zones, preserved follicular architecture
- Mixed variant: features of both
Fine needle aspiration is INADEQUATE; excisional biopsy is required.
2. Multicentric Distribution
Enlarged lymph nodes in at least 2 lymph node stations on imaging (CT or MRI of neck, chest, abdomen, pelvis):
- Short-axis diameter >1 cm
- At least 2 anatomically distinct regions (cervical, axillary, mediastinal, abdominal, pelvic, retroperitoneal)
3. Minor Criteria (At Least 2 of 11)
Must include at least 1 laboratory criterion AND at least 1 clinical criterion:
| Category | Minor Criterion |
|---|---|
| Laboratory (at least 1) | Elevated CRP (>10 mg/L) or ESR (>15 mm/h) |
| Anemia (Hgb <12.5 g/dL men, <11.5 women) | |
| Thrombocytopenia (platelets <150) OR thrombocytosis (>400) | |
| Hypoalbuminemia (<3.5 g/dL) | |
| Renal dysfunction (eGFR <60 mL/min) or proteinuria (>150 mg/24h) | |
| Polyclonal hypergammaglobulinemia (total gamma globulin >1.7 g/dL) | |
| Elevated alkaline phosphatase | |
| Clinical (at least 1) | Constitutional symptoms (night sweats, fever, weight loss, fatigue, hyperhidrosis) |
| Hepatomegaly and/or splenomegaly | |
| Fluid accumulation (peripheral edema, ascites, pleural or pericardial effusion) | |
| Eruptive cherry hemangiomatosis OR violaceous papules | |
| Lymphocytic interstitial pneumonitis (LIP) |
4. Exclusion of HHV-8 Infection
- Lymph node LANA-1 immunohistochemistry NEGATIVE (LANA-1 = latent nuclear antigen-1, the gold standard marker of HHV-8 infection)
- HHV-8 PCR may be supportive but LANA-1 IHC is the standard
- HHV-8 positivity reclassifies the patient as HHV-8-associated MCD (different treatment paradigm)
5. Exclusion of Alternative Diagnoses
- Infections: HIV, HHV-8, EBV, CMV, syphilis, TB, opportunistic infections
- Autoimmune disease: SLE, juvenile idiopathic arthritis, autoimmune lymphoproliferative syndrome, IgG4-RD
- Malignancy: lymphoma (Hodgkin, NHL), POEMS, multiple myeloma, follicular dendritic cell sarcoma, primary effusion lymphoma
- POEMS syndrome: distinct entity; concurrent MCD reclassifies as POEMS-associated MCD
S3. TAFRO and NOS-IPL Subtypes
Two Major iMCD Subtypes
The CDCN 2017 criteria formalized two iMCD clinical subtypes that have substantially different presentations, treatment urgency, and prognosis:
| Feature | iMCD-TAFRO | iMCD-NOS (including IPL) |
|---|---|---|
| Onset | Acute, severe | Subacute to chronic |
| Thrombocytopenia | Severe (often <50,000) | Variable, less severe |
| Anasarca | Prominent (ascites, pleural/pericardial effusion, edema) | Variable, less prominent |
| Fever | High-grade, prolonged | Variable |
| Reticulin fibrosis BM | Present with megakaryocyte hyperplasia | Less prominent |
| Organomegaly | Prominent | Variable |
| Lymphadenopathy | Often mild to moderate | Often more prominent |
| Hypergammaglobulinemia | NORMAL or LOW gamma globulins (paradoxical) | Polyclonal hypergammaglobulinemia (frequent) |
| Renal dysfunction | Common, may be severe | Less prominent |
| Short-term mortality without treatment | Substantial | Lower |
| First-line therapy | Siltuximab + high-dose corticosteroids; consider cytotoxic chemotherapy early | Siltuximab monotherapy or with steroids |
TAFRO Subtype
TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, Organomegaly) was originally described in Japanese patients but is now recognized globally. Distinctive features:
- Acute severe presentation: often hospitalized at diagnosis with multiple-organ involvement
- Severe thrombocytopenia: platelets often <50,000, sometimes <30,000, with bleeding risk
- Profound anasarca: bilateral pleural effusions, pericardial effusion, ascites, peripheral edema with associated hypoalbuminemia
- Bone marrow shows reticulin fibrosis with megakaryocyte hyperplasia (often misinterpreted as primary myelofibrosis or MDS)
- Hepatosplenomegaly common
- Renal dysfunction: AKI, proteinuria, often requiring renal replacement therapy in severe cases
- NORMAL or LOW gamma globulins: distinguishes from typical iMCD-NOS which has polyclonal hypergammaglobulinemia
- Substantial short-term mortality without prompt treatment (20-30 percent in some series)
iMCD-NOS (Including IPL Variant)
iMCD-NOS (Not Otherwise Specified) encompasses iMCD that does not meet TAFRO criteria. A recognized subset is the idiopathic plasmacytic lymphadenopathy (IPL) variant characterized by:
- Generalized lymphadenopathy with plasma cell histology
- Marked polyclonal hypergammaglobulinemia (often gamma globulin >3-5 g/dL)
- Anemia, often Coombs-positive
- Less acute presentation than TAFRO
- Better short-term prognosis but chronic course
Recognition of TAFRO — Why It Matters
Recognizing TAFRO at presentation is crucial because:
- Treatment urgency differs: TAFRO requires immediate aggressive therapy (often hospitalization, ICU consideration)
- Treatment intensity differs: TAFRO usually requires combination siltuximab + high-dose corticosteroids, with early consideration of cytotoxic chemotherapy
- Prognosis differs: TAFRO has higher short-term mortality and lower response rate to anti-IL-6 monotherapy
- Differential is different: TAFRO can mimic primary myelofibrosis (bone marrow reticulin fibrosis), TTP (thrombocytopenia + organ dysfunction), or autoimmune disease
S4. Histopathology and Differential Diagnosis
Histopathologic Variants
Hyaline-Vascular Variant (Predominant in UCD)
| Histologic Feature | Description |
|---|---|
| Regressed germinal centers | “Burned out” appearance, atrophic, reduced cellularity |
| Onion-skin mantle zones | Concentric layering of mantle zone lymphocytes around regressed germinal center |
| Penetrating vessels | Sclerosed hyalinized vessel penetrating into germinal center (“lollipop” appearance) |
| Dendritic cell prominence | CD21 and CD23 positive follicular dendritic cells |
| Twinning of germinal centers | Multiple regressed germinal centers in single follicle |
| Interfollicular vascular proliferation | High vascular density between follicles |
Plasma Cell Variant (More Common in MCD)
| Histologic Feature | Description |
|---|---|
| Hyperplastic germinal centers | Enlarged, active germinal centers (opposite of hyaline-vascular) |
| Plasma cell sheets | Diffuse plasma cells in interfollicular zones, often polytypic by light chain IHC |
| Preserved follicular architecture | Less vascular proliferation than hyaline-vascular |
| Polyclonal nature | Lambda/kappa light chain ratio normal (excludes plasma cell neoplasm) |
Mixed Variant
Combined features of hyaline-vascular and plasma cell variants; intermediate behavior.
Required Immunohistochemistry
| IHC Marker | Purpose |
|---|---|
| HHV-8 LANA-1 | NEGATIVE in iMCD; positive reclassifies as HHV-8-associated MCD |
| CD20, CD3 | B and T cell distribution; rule out lymphoma |
| CD21, CD23 | Follicular dendritic cell network |
| Kappa/lambda light chains | Polyclonal in iMCD; monoclonal suggests plasma cell neoplasm or POEMS |
| IgG4 | Excludes IgG4-related disease (IgG4+ >10/HPF or IgG4/IgG >40%) |
| Ki-67 | Proliferation index; very high suggests aggressive lymphoma |
| CD138 | Plasma cell highlight |
Differential Diagnosis
| Differential | Distinguishing Features |
|---|---|
| HHV-8-associated MCD | HIV positive or immunocompromised; LANA-1 IHC positive; different treatment paradigm (rituximab + ART) |
| POEMS syndrome | Polyneuropathy, organomegaly, endocrinopathy, lambda M-protein, elevated VEGF, osteosclerotic lesions; ~10% of POEMS have concurrent MCD |
| IgG4-related disease | Storiform fibrosis, IgG4+ plasma cells >10/HPF, IgG4/IgG >40%; elevated serum IgG4 |
| Hodgkin lymphoma | Reed-Sternberg cells, CD30 and CD15 positive; clinical and histologic distinction usually clear |
| Non-Hodgkin lymphoma | Clonal lymphoproliferation; B-cell or T-cell receptor rearrangement by PCR; distinct histology |
| Angioimmunoblastic T-cell lymphoma (AITL) | T follicular helper phenotype (CD4+ CD10+ PD-1+ BCL6+); arborizing high endothelial venules; can closely mimic Castleman |
| Plasmablastic lymphoma | Plasmablastic morphology, HIV association, EBV positive, c-MYC rearrangement |
| Rosai-Dorfman disease | Sinus histiocytosis with massive lymphadenopathy; S100+ histiocytes with emperipolesis |
| Autoimmune lymphoproliferative syndrome (ALPS) | FAS pathway mutations; double-negative T cells; family history |
| Primary myelofibrosis (TAFRO mimic) | JAK2/CALR/MPL mutations; bone marrow histology distinct; no Castleman lymph nodes |
| TTP (TAFRO mimic) | Microangiopathic hemolytic anemia, schistocytes, neurologic features, ADAMTS13 <10% |
| Systemic lupus erythematosus | ANA, anti-dsDNA, multi-system criteria-based diagnosis |
S5. Siltuximab, Tocilizumab, and Refractory Disease Management
CDCN Treatment Guidelines — First-Line
The Castleman Disease Collaborative Network treatment guidelines (Blood 2018) recommend risk-stratified first-line therapy based on disease severity:
Non-Severe iMCD (No Severe Organ Dysfunction, No TAFRO)
| Therapy | Dose | Comments |
|---|---|---|
| Siltuximab (preferred, FDA-approved) | 11 mg/kg IV every 3 weeks | Chimeric anti-IL-6 monoclonal antibody; van Rhee 2014 RCT: 34% durable response vs 0% placebo |
| Tocilizumab (alternative) | 8 mg/kg IV every 2 weeks | Anti-IL-6 receptor antibody; standard of care in Japan; not FDA-approved for iMCD but widely used |
| Corticosteroids (adjunct) | Prednisone 1 mg/kg PO daily, taper | Often added for symptomatic relief during siltuximab response evaluation |
Severe iMCD (Organ Dysfunction, TAFRO, Rapid Progression)
| Component | Approach |
|---|---|
| Siltuximab + high-dose corticosteroids | Siltuximab 11 mg/kg IV q3 weeks + methylprednisolone 1-2 mg/kg/day IV initially with gradual taper |
| Consider cytotoxic chemotherapy early | R-CHOP, CHOP, or CVAD if rapid deterioration or organ failure |
| Supportive care | ICU monitoring if severe; platelet transfusion if active bleeding; renal replacement therapy for severe AKI; therapeutic thoracentesis/paracentesis for symptomatic effusions |
Siltuximab Pivotal RCT Details
The van Rhee 2014 randomized placebo-controlled trial (Lancet Oncology) established siltuximab ‘s role:
- Design: 79 iMCD patients randomized 2:1 to siltuximab vs placebo, both with best supportive care
- Primary endpoint: durable tumor and symptomatic response (combined improvement in lymph node, organomegaly, laboratory, and symptom measures)
- Results: siltuximab 34 percent durable response vs 0 percent placebo (P<0.0001)
- Safety: well tolerated; infections, pruritus, fatigue most common AEs
- Approval: FDA approved 2014 specifically for iMCD; first-ever iMCD-specific approval
Tocilizumab Alternative
Tocilizumab (anti-IL-6 receptor antibody, rather than direct IL-6 neutralization like siltuximab) has been the standard of care for iMCD in Japan since 2005 based on the Nishimoto trial demonstrating clinical and laboratory improvement. Dosing 8 mg/kg IV every 2 weeks. Not FDA-approved for iMCD in the United States but widely used off-label internationally. Mechanism overlap with siltuximab makes them generally interchangeable for clinical purposes; choice is often determined by regional availability, cost, and physician familiarity.
Response Assessment
Response to anti-IL-6 therapy is assessed at 3 and 6 months using composite criteria:
- Tumor response: lymph node size reduction, organomegaly regression
- Laboratory response: normalization of CRP/ESR, hemoglobin improvement, albumin improvement, normalization of gamma globulins
- Symptomatic response: resolution of constitutional symptoms, weight gain, functional improvement
- Effusion resolution: ascites, pleural, pericardial effusion improvement
Refractory iMCD Management
For patients who fail to respond to anti-IL-6 therapy within 3-6 months or who progress on therapy, the CDCN treatment guidelines recommend:
| Second-Line Option | Dose | Comments |
|---|---|---|
| Rituximab | 375 mg/m2 IV weekly x 4 weeks | B-cell depletion; effective in some iMCD subsets (autoimmune-driven) |
| Cytotoxic combination chemotherapy | R-CHOP, CHOP, or CVAD x 4-6 cycles | Used for severe refractory disease or TAFRO with multi-organ failure |
| Lenalidomide | 25 mg PO daily on days 1-21 of 28-day cycle | Immunomodulator; case series support; VTE prophylaxis required |
| Thalidomide | 100-400 mg PO daily | Older immunomodulator; substantial neuropathy and VTE risk |
| Sirolimus (mTOR inhibitor) | Trough-guided dosing | Targets PI3K/AKT/mTOR pathway; case series and small trials suggest benefit, especially in refractory cases |
| Ruxolitinib (JAK inhibitor) | 15 mg PO BID typical | Targets JAK-STAT signaling downstream of IL-6 and other cytokines; emerging case series support, especially for refractory TAFRO |
| Hematopoietic stem cell transplant | Autologous or allogeneic | Reserved for severe refractory disease; reported in case series |
Unicentric Castleman Disease Management
Unicentric Castleman disease (UCD) management is fundamentally different from MCD and iMCD:
- Complete surgical excision is the standard treatment, curative in approximately 90-95 percent of cases
- Radiation therapy for unresectable lesions (e.g., extensive mediastinal disease)
- Embolization may be considered for hypervascular lesions to reduce intraoperative bleeding
- Anti-IL-6 therapy or rituximab rarely needed; reserved for symptomatic systemic disease in plasma cell variant UCD
- Long-term surveillance: clinical follow-up; recurrence rare after complete excision
Long-Term Care and Surveillance
- Periodic imaging: CT chest/abdomen/pelvis every 3-6 months during active treatment; every 6-12 months once stable
- Laboratory monitoring: CBC, CMP, CRP, ESR, immunoglobulins; every 1-3 months during active treatment
- Vaccination: avoid live vaccines during immunosuppression; consider hepatitis B vaccination given anti-IL-6 long-term use
- Infection prophylaxis: consider Pneumocystis prophylaxis during prolonged corticosteroid use
- Cancer surveillance: elevated risk of secondary lymphoma and other malignancies; routine age-appropriate screening
- Pregnancy considerations: siltuximab and tocilizumab category B-C; counseling for women of reproductive age
S6. Practice Insights — Lessons from the Lymphoproliferative Disorders Clinic
1. Excisional lymph node biopsy mandatory — FNA and core biopsy inadequate
The single highest-yield diagnostic rule in experienced practice is that Castleman disease diagnosis REQUIRES excisional lymph node biopsy with comprehensive immunohistochemistry. Fine needle aspiration and core biopsy do not provide adequate architecture for Castleman histology recognition or for the IHC panel needed (HHV-8 LANA-1, CD20, CD21, CD23, kappa/lambda, IgG4, Ki-67). clinicians have seen multiple patients labeled with iMCD on core biopsy who proved to have angioimmunoblastic T-cell lymphoma, IgG4-RD, or POEMS-associated MCD when excisional biopsy was finally obtained. The standard now is to insist on excisional biopsy before committing to iMCD-directed therapy.
2. TAFRO requires combination siltuximab + steroids upfront, not monotherapy
In experienced hands, TAFRO patients started on siltuximab monotherapy without concurrent high-dose corticosteroids deteriorate over the weeks needed for siltuximab response evaluation. Experienced practice has shifted to initiating combination siltuximab + IV methylprednisolone 1-2 mg/kg/day at TAFRO diagnosis, with consideration of early cytotoxic chemotherapy (R-CHOP or CVAD) for patients with multi-organ failure or rapid progression. The combination upfront has reduced ICU mortality in the TAFRO experience substantially.
3. CDCN-affiliated expert center consultation for every iMCD diagnosis
iMCD is sufficiently rare that even academic hematologists see only occasional cases, and treatment selection benefits substantially from consultation with CDCN-affiliated expert centers (the Castleman Disease Collaborative Network maintains a list). Experienced practice is to engage CDCN expert consultation for every new iMCD diagnosis, particularly TAFRO cases and refractory disease. The expert centers offer access to clinical trials, second opinions on histopathology, and refined treatment algorithms developed from collective experience that no single non-specialty center can replicate.
4. POEMS workup in every iMCD — the overlap is meaningful
Approximately 10 percent of POEMS patients have concurrent MCD that meets Castleman histology criteria, and the management is fundamentally different (POEMS-directed therapy with lenalidomide-dexamethasone-ASCT rather than anti-IL-6). Experienced practice is to send serum and urine immunofixation, serum free light chains, serum VEGF, and skeletal survey or FDG-PET in every newly diagnosed iMCD to rule out concurrent or evolving POEMS. The lambda M-protein, elevated VEGF, and osteosclerotic lesions of POEMS reclassify the disease and change the entire treatment paradigm.
Personal protocol adjustments beyond the published guideline
- Excisional lymph node biopsy with comprehensive IHC mandatory, FNA/core biopsy inadequate. The guideline supports excisional biopsy; experienced practice formalizes this as a non-negotiable requirement before initiating iMCD-directed therapy, because architectural details and full IHC panel cannot be assessed on FNA or core biopsy.
- Combination siltuximab + IV methylprednisolone upfront for TAFRO, not monotherapy. The CDCN guideline supports combination for severe disease; experienced practice formalizes combination as the standard initial regimen for all TAFRO patients, with early consideration of cytotoxic chemotherapy if multi-organ failure.
- CDCN expert center consultation for every new iMCD diagnosis. The guideline encourages specialty consultation; experienced practice mandates it for every iMCD case, particularly TAFRO and refractory disease, because of the rarity and complexity of management.
- POEMS workup (immunofixation, free light chains, VEGF, FDG-PET) in every newly diagnosed iMCD. The guideline notes POEMS overlap; experienced practice mandates the full POEMS workup at iMCD diagnosis because identifying concurrent POEMS reclassifies the disease and fundamentally changes treatment paradigm.
Four-panel personal framework: the Castleman disease classification tree from UCD through MCD subtypes to iMCD (panel 1), the CDCN 2017 five-component diagnostic criteria checklist (panel 2), the TAFRO versus NOS-IPL subtype comparison grid with treatment paradigm differences (panel 3), and the severity-stratified treatment algorithm with refractory escalation pathway (panel 4). Approximate ranges; not institutional outcome data.
S7. Frequently Asked Questions
- Smoldering Multiple Myeloma: Risk Stratification, Surveillance, and When to Treat
- Iron Deficiency Anemia: Evaluation, Etiology Workup, and Evidence-Based Repletion
- Venous Thromboembolism — DVT and Pulmonary Embolism Management
- Hereditary Spherocytosis: Diagnosis, Severity, and Splenectomy Decisions
- Sickle Cell Vaso-Occlusive Crisis: ED Management and Pain Control
- Multiple Myeloma: Diagnosis, R-ISS Staging, and Induction/Transplant Pathways